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Idiopathic membranous nephropathy is a common cause of nephrotic syndrome, and has
been reported as a cause of idiopathic primary glomerulonephropathy in up to 90% of
patients. However, the treatment options remain controversial. We report two cases of
idiopathic membranous nephropathy that were treated with rituximab. A 54-year-old
man and a 64-year old man were admitted for rituximab therapy. They had previously
been treated with combinations of immunosuppressive agents including cyclophospha-
mide, cyclosporine, mycophenolate, and steroids. However, the patients' heavy proteinuria
was not resolved. Both patients received rituximab therapy, 2 weeks apart. After several
months of follow-up and a second round of rituximab treatment for each patient, their
proteinuria decreased and partial remission of disease was achieved in both patients.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Membranous nephropathy is a common cause of nephrotic
syndrome in adults [1]. With a relatively slow disease pro-
gression, membranous nephropathy progresses to end-stage
renal disease in approximately 40% of patients [2]. Currently,
treatment includes corticosteroids, alkylating agents, cyclos-
porine, mycophenolate mofetil, and tacrolimus [1]. However,
drug toxicity and persistent heavy proteinuria resistant to
these drugs are problematic in many patients. In rodent
models, B cells have been implicated in the pathogenesis of
idiopathic membranous nephropathy [3]. Therefore, rituxi-
mab, a selective B cell targeting agent, has emerged as an
alternative treatment option for membranous nephropathy.
Several studies evaluating the effectiveness of rituximab
therapy for membranous nephropathy have shown promising
results [2,4,5]. However, the treatment of idiopathic membra-




-G Kim).in Korea. We report two cases of membranous nephropathy
showing partial remission after rituximab treatment.Case reports
Case 1
A 64-year-old man with a 21-year history of idiopathic
membranous nephropathy presented with increased proteinuria.
He had been taking angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers with no response. Mycophenolate
1,000 mg/day and prednisolone 30mg/day were administered for
1 year, followed by cyclophosphamide 100mg/day and predniso-
lone 5mg/day for 6 months; both regimens were unsuccessful for
resolving his proteinuria. Cyclosporine 200mg/day and predniso-
lone 5mg/day were subsequently prescribed for 5 years, with a
temporary decrease in proteinuria for 2 years to 2 g/day; how-
ever, proteinuria gradually increased to 5 g/day. Mycophenolate
1,000 mg/day was then added to the cyclosporine and predniso-
lone regimen. However, azotemia exacerbation, serum creatinine
level of 1.92 mg/dL, and persistent heavy proteinuria were noted.
Despite these immunosuppressive treatments, the patient'sshed by Elsevier. This is an open access article under the CC BY-NC-ND
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To exclude the possibility of other renal diseases, a renal biopsy
was performed on July 30, 2010. A complete blood count at the
time of the renal biopsy showed normocytic and normochromic
anemia (hemoglobin¼11.3 g/dL), with a normal white blood cell
and platelet count. Liver function tests were normal. Blood urea
nitrogen (BUN) and creatinine levels were 23.7 mg/dL and
1.86 mg/dL, respectively. Renal biopsy showed stage III/IV mem-
branous nephropathy. Because previous immunosuppressant regi-
mens were ineffective, rituximab 1 g was administered on Day
1 and Day 15. Valsartan 80mg was continued irrespective of
rituximab. The patient did not experience any side effects during
and after the infusion. Before rituximab infusion, the number of
CD19(+) B cells was 425/μL. Two months and 5 months after
rituximab therapy, urine protein/creatinine ratios decreased to
5.55 mg/mg and 1.14 mg/mg, respectively. However, the patient's
proteinuria increased slowly thereafter. After 6 months, the
number of CD19(+) B cells decreased to 37/μL, but it rose to
148/μL at 8 months. After 10 months, the urine protein/creatinine
ratio increased to 5.17 mg/mg. With the increase of proteinuria
and edema, the second round of rituximab treatment was
performed according to the same dosage and schedule as the ﬁrst
treatment. Six months later, the patient's urine protein/creatinine
ratio decreased to 2.95 mg/mg and the number of CD19(+) B cells
fell to 14/μL (Fig. 1A). However, the estimated glomerular ﬁltration
rate (GFR) was declined (Fig. 1B). These results indicate that
rituximab could be used for the decrement of proteinuria.Figure 1. Data from Case 1. (A) Proteinuria was increased to 12 g/day.
Rituximab was ﬁrst administered once daily, 2 weeks apart. Urine protein/
creatinine ratio decreased to 1.12 mg/mg after 6 months, but the urine
protein/creatinine ratio increased to 5.17 mg/mg soon after. A second
round of rituximab was administered after 10 months of follow-up. The
urine protein/creatinine ratio decreased to 2.95 mg/mg. Partial remission
was achieved. (B) The estimated GFR of Case 1 showed worsening after
rituximab infusion. GFR, glomerular ﬁltration rate.Case 2
A 54-year-old man presented with generalized edema and
foamy urine. He had been diagnosed with stage II/IV membranous
nephropathy about 2 years prior. The patient was initially treated
with angiotensin-converting enzyme inhibitor and angiotensin
receptor blocker. However, nephrotic-range proteinuria persisted
at approximately 6–7 g/day after 6 months. Cyclophosphamide
125mg/day and prednisolone 10mg/day were then administered
for 5 months, with no response. Mycophenolate 2,000 mg/day
and prednisolone 10mg/day were subsequently administered for
5 months; the patient's proteinuria temporarily decreased to 0.3 g/
day, but soon increased to 5.0 g/day. Mycophenolate was replaced
by cyclosporine 200mg/day, but with no response. Finally, com-
bination treatment of mycophenolate 2,000 mg/day and cyclos-
porine 150mg/day was tried, but this regimen failed to elicit even
partial remission. Because these treatment regimens proved
unsuccessful, the patient was admitted for rituximab treatment.
Complete blood count indicated normocytic and normochromic
anemia (hemoglobin¼10.7 g/dL), with normal white blood cell
and platelet counts. Total protein was 4.4 g/dL, albumin was 2.3 g/
dL, and liver function tests were normal. BUN and creatinine levels
were 34.6 mg/dL and 1.17 mg/dL, respectively. Spot urine protein/
creatinine ratio was 7.95 mg/mg. Rituximab 1 g was administered
on Day 1 and Day 15. Valsartan 80mg/day was continued
irrespective of treatment. One month after the initiation of
rituximab treatment, the patient's urine protein/creatinine ratio
decreased to 3.45 mg/mg and generalized edema improved. After
4 months, the patient's urine protein/creatinine ratio decreased
further to 1.66 mg/mg, and the number of CD19(+) B cells was
11/μL. After 6 months, however, the urine protein/creatinine ratio
increased to 7.42 mg/mg, and a second round of rituximab
treatment was performed. Five months later, the patient's urine
protein/creatinine ratio fell to 0.80 mg/mg (Fig. 2A). The estimated
GFR improved 17% after rituximab therapy (Fig. 2B).Discussion
These two cases presented here demonstrate the potential
of rituximab treatment for idiopathic membranous nephro-
pathy in patients who do not respond to usual immunosup-
pressive treatment. During 1 year and 2 years of follow-up,
the urine protein/creatinine ratios in our cases decreased after
rituximab treatment. However, approximately 6 months fol-
lowing the initial treatment, rituximab was again required, and
complete remission was not achieved.
Current treatments for idiopathic membranous nephropathy
include steroids and immunosuppressant drugs, which are not
disease-speciﬁc and are associated with serious risks of toxicity
in the renin–angiotensin system blockade in nonresponders [2].
Two types of immunosuppressants are typically used in combi-
nationwith corticosteroids: alkylating agents (cyclophosphamide
and chlorambucil) and calcineurin inhibitors (cyclosporine or
tacrolimus) [1]. Despite these powerful immunomodulating drug
combinations, refractory membranous nephropathy cases have
been reported. For these refractory membranous nephropathies,
other management strategies have been tried with mycopheno-
late mofetil, tacrolimus, and intravenous immunoglobulin [6].
According to the Heymann nephritis model applied in rodent
studies, B cells play an important role in the pathogenesis
of idiopathic membranous nephropathy [7,8]. Recently, several
podocyte antigens, including neutral endopeptidase, M-type
Figure 2. Data from Case 2. (A) Urine protein/creatinine ratio increased to
7.95 mg/mg. Rituximab was administered once daily, 2 weeks apart. Six
months later, rituximab was administered again due to an increase of
proteinuria. Partial remission was achieved after rituximab infusion
4 months later. (B) The estimated GFR of Case 2 shows an improvement
of 17% after rituximab therapy. GFR, glomerular ﬁltration rate.
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dismutase 2, were identiﬁed as targets for autoantibodies in
patients with membranous nephropathy [9]. Rituximab, a chi-
meric antibody against B cell CD20 antigen, produces speciﬁc
depletion of these cells for approximately 12 months [10]. Treat-
ment for this antibody-mediated disease can then be optimized
during the period of B cell depletion. Rituximab treatment for
idiopathic membranous nephropathy has been reported. Treat-
ment protocols have involved two regimens: four weekly doses of
375mg/m2, which is the standard dose for treatment of lym-
phoma, and two doses of 1 g given at 2-week intervals, which is
standard for rheumatoid arthritis. Ruggenenti et al. [2] prospec-
tively treated eight nephrotic patients with persistent proteinuria
of 43.5 g/day. Rituximab (375mg/m2) was administered as four
weekly infusions. At 3 months and 12 months, proteinuria
signiﬁcantly decreased from 8.674.2 [mean7standard deviation
(SD)] to 4.373.3 g/day (−51%, Po0.005) and 3.072.5 (−66%,
Po0.005) g/day, respectively. Fervenza et al. [4] conducted a
prospective, open-labeled pilot trial of rituximab treatment in 15
severely nephrotic patients with proteinuria refractory to
angiotensin-converting enzyme inhibition and/or receptor block-
ade. Rituximab (1 g) was administered twice, 2 weeks apart; at
6 months, patients with persistent proteinuria but recovered B cell
counts were given a second round of rituximab treatment.
Proteinuria was signiﬁcantly decreased from baseline proteinuria
of 13.075.7 g/day (range, 6.1–23.5 g/day) to 6.077.3 g/day at 12
months (−54%; range, 0.2–20 g/day; Po0.001).
Fervenza et al. [5] also evaluated the optimal rituximab
dose for idiopathic membranous nephropathy, using the same
four weekly dose schedule as previously used by Ruggenenti
et al. [2] as well as the two doses of rituximab as in theirprevious work (1 g each; 48% reduction in mean protein
levels). At a 12-month follow-up, they found no signiﬁcant
difference in the response rate. For this reason, we treated
patients with 1 g of rituximab at 2-week intervals, considering
patient convenience and possible difﬁculties associated with
weekly hospital visits for rituximab injections.
In our two cases, rituximab regimens were not only complied
with, but were also effective for gradually reducing proteinuria.
Previously used immunosuppressant agents, including cyclopho-
sphamide, cyclosporine, mycophenolate mofetil, and steroids,
failed to achieve the same outcome. However, the estimated
GFR of the ﬁrst case declined with proteinuria reduction, and
proteinuria did not decrease to less than 1 g/day. The results in
the ﬁrst case were not as impressive as in the second case. Given
the possible side effects of rituximab, our patients were treated
with 100 mg methylprednisolone, 650 mg acetaminophen, and
4 mg chlorpheniramine before rituximab infusion. Although we
did not observe any side effects such as ﬂushing or pruritus,
other studies have reported mostly mild rituximab infusion
reactions in 20–40% of cases [11]. The formation of antichimeric
antibodies to rituximab is found in approximately 33% of patients
with poor B cell depletion. Furthermore, B cell depletion can
predispose patients to severe viral infections such as progressive
multifocal leukoencephalopathy after rituximab therapy. In 2009,
the US Food and Drug Administration reported a third case of
progressive multifocal leukoencephalopathy in a patient with
rheumatoid arthritis [12].
As illustrated in our two cases, rituximab therapy could be a
feasible treatment option with minimal side effects for idiopathic
membranous nephropathy patients who are refractory to immu-
nosuppressive therapies. Compared with recent studies, our
follow-up periods were relatively short, and a longer follow-up
period would be desirable. Ruggenenti et al. reported that remis-
sion was achieved over a median of 7.1 months [13]. Another
report showed that proteinuria tends to decline slowly and
remissions may occur up to 2 years after rituximab treatment
[14]. Combinations of rituximab with abbreviated courses of other
agents with quicker onset of antiproteinuric effects is under
investigation [13].The timing, duration, and speciﬁc dosing of
rituximab remain unclear. Large, multi-center, randomized trials
with long-term follow-up are needed to verify the long-term
tolerability and overall survival beneﬁt of rituximab therapy.Conﬂicts of interest
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